Top > Search of International Patents > Inhibitor of HMGB protein-mediated immune response activation, and screening method

Inhibitor of HMGB protein-mediated immune response activation, and screening method

Foreign code F130007604
File No. AF22-02WO
Posted date Aug 9, 2013
Country United States of America
Application number 201113823913
Gazette No. 20130183348
Gazette No. 9186371
Date of filing Sep 14, 2011
Gazette Date Jul 18, 2013
Gazette Date Nov 17, 2015
International application number JP2011071023
International publication number WO2012036215
Date of international filing Sep 14, 2011
Date of international publication Mar 22, 2012
Priority data
  • P2010-209587 (Sep 17, 2010) JP
  • P2011-138825 (Jun 22, 2011) JP
  • 2011WO-JP71023 (Sep 14, 2011) WO
Title Inhibitor of HMGB protein-mediated immune response activation, and screening method
Abstract (US9186371)
Provided are an inhibitor of activation of an immune response mediated by an HMGB protein, the inhibitor containing at least one compound selected from the group consisting of a phosphorothioate oligonucleotide and a derivative thereof, and a method of screening for an inhibitor or enhancer of activation of an immune response mediated by an HMGB protein.
Scope of claims [claim1]
1. A method of inhibiting activation of an immune response mediated by a high-mobility group box (HMGB) protein, the method comprising administering to a subject in need thereof a phosphorothioate oligonucleotide of 20 to 40 nucleotides in length in an amount effective to inhibit an immune response in the subject, wherein
the phosphorothioate oligonucleotide binds to HMGB protein,
the phosphorothioate oligonucleotide does not have an unmethylated CG sequence, and
the phosphorothioate oligonucleotide does not have a methylated guanine.
[claim2]
2. The method according to claim 1, wherein the phosphorothioate oligonucleotide is a phosphorothioate oligonucleotide consisting of: a nucleotide sequence as set forth in SEQ ID NO: 40; or
a nucleotide sequence having deletion, substitution, or addition of one or more nucleotides in the nucleotide sequence as set forth in SEQ ID NO: 40 and having a binding ability to an HMGB protein.
[claim3]
3. The method according to claim 1, wherein the phosphorothioate oligonucleotide inhibits a binding between a nucleic acid activating the immune response and the HMGB protein in a cell.
[claim4]
4. The method according to claim 1, wherein the activation of an immune response mediated by an HMGB protein is selected from the group consisting of antigen-specific adaptive immune system, multiple sclerosis, excessive immune response to a dead cell, organ transplant rejection, autoimmune disease, inflammatory bowel disease, allergy, septicemia, tumor growth by inflammation and inflammatory disease caused by a nucleic acid-containing pathogen.
[claim5]
5. The method according to claim 1, wherein the phosphorothioate oligonucleotide is a phosphorothioate oligonucleotide consisting of: a nucleotide sequence as set forth in SEQ ID NO: 40; or
a nucleotide sequence having deletion, substitution, or addition of one to five nucleotides in the nucleotide sequence as set forth in SEQ ID NO: 40 and having a binding ability to an HMGB protein.
[claim6]
6. The method according to claim 1, wherein the activation of an immune response mediated by an HMGB protein causes multiple sclerosis or septicemia.
[claim7]
7. The method according to claim 5, wherein the activation of an immune response mediated by an HMGB protein causes multiple sclerosis or septicemia.
[claim8]
8. The method according to claim 1, wherein the phosphorothioate oligonucleotide is a phosphorothioate oligonucleotide consisting of: a nucleotide sequence as set forth in SEQ ID NO: 40; or
a nucleotide sequence having deletion, substitution, or addition of one to three nucleotides in the nucleotide sequence as set forth in SEQ ID NO: 40 and having a binding ability to an HMGB protein.
[claim9]
9. The method according to claim 8, wherein the activation of an immune response mediated by an HMGB protein causes multiple sclerosis or septicemia.
[claim10]
10. The method according to claim 1, wherein the phosphorothioate oligonucleotide is a phosphorothioate oligonucleotide consisting of a nucleotide sequence as set forth in SEQ ID NO: 40.
[claim11]
11. The method according to claim 10, wherein the activation of an immune response mediated by an HMGB protein causes multiple sclerosis or septicemia.
[claim12]
12. The method according to claim 1, wherein the phosphorothioate oligonucleotide is a phosphorothioate oligonucleotide comprising: a nucleotide sequence as set forth in SEQ ID NO: 40; or
a nucleotide sequence having deletion, substitution, or addition of one or more nucleotides in the nucleotide sequence as set forth in SEQ ID NO: 40 and having a binding ability to an HMGB protein.
[claim13]
13. The method according to claim 1, wherein the phosphorothioate oligonucleotide is a phosphorothioate oligonucleotide comprising: a nucleotide sequence as set forth in SEQ ID NO: 40; or
a nucleotide sequence having deletion, substitution, or addition of one to five nucleotides in the nucleotide sequence as set forth in SEQ ID NO: 40 and having a binding ability to an HMGB protein.
[claim14]
14. The method according to claim 13, wherein the activation of an immune response mediated by an HMGB protein causes multiple sclerosis or septicemia.
[claim15]
15. The method according to claim 1, wherein the phosphorothioate oligonucleotide is a phosphorothioate oligonucleotide comprising: a nucleotide sequence as set forth in SEQ ID NO: 40; or
a nucleotide sequence having deletion, substitution, or addition of one to three nucleotides in the nucleotide sequence as set forth in SEQ ID NO: 40 and having a binding ability to an HMGB protein.
[claim16]
16. The method according to claim 15, wherein the activation of an immune response mediated by an HMGB protein causes multiple sclerosis or septicemia.
[claim17]
17. The method according to claim 1, wherein the phosphorothioate oligonucleotide is a phosphorothioate oligonucleotide comprising a nucleotide sequence as set forth in SEQ ID NO: 40.
[claim18]
18. The method according to claim 17, wherein the activation of an immune response mediated by an HMGB protein causes multiple sclerosis or septicemia.
[claim19]
19. The method according to claim 1, wherein the activation of an immune response mediated by an HMGB protein causes an inflammatory disease.
[claim20]
20. The method according to claim 1, wherein the phosphorothioate oligonucleotide is unmethylated.
[claim21]
21. The method according to claim 1, wherein the phosphorothioate oligonucleotide does not comprise a CG sequence.
  • Inventor, and Inventor/Applicant
  • TANIGUCHI TADATSUGU
  • YANAI HIDEYUKI
  • JAPAN SCIENCE AND TECHNOLOGY AGENCY
IPC(International Patent Classification)
Reference ( R and D project ) CREST Etiological Basics of and Techniques for Treatment of Allergic and Autoimmune Diseases AREA
Please contact us by E-mail or facsimile if you have any interests on this patent.

PAGE TOP

close
close
close
close
close
close